Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Condition(s):Recessive Dystrophic Epidermolysis BullosaLast Updated:November 3, 2022Recruiting
Include Studies Not Open or Pending
Condition(s):Recessive Dystrophic Epidermolysis BullosaLast Updated:November 3, 2022Recruiting
Condition(s):Junctional Epidermolysis BullosaLast Updated:April 7, 2020Recruiting
Condition(s):Junctional Epidermolysis BullosaLast Updated:November 3, 2022Recruiting
Condition(s):Catheter InfectionLast Updated:March 26, 2024Recruiting
Condition(s):Anterior Cruciate Ligament InjuriesLast Updated:February 5, 2024Not yet recruiting
Condition(s):Healthy VolunteersLast Updated:May 18, 2022Recruiting
Condition(s):Fracture Open TibiaLast Updated:December 21, 2023Recruiting
Condition(s):Bronchiectasis With Acute ExacerbationLast Updated:January 17, 2024Not yet recruiting
Condition(s):Cat-Scratch DiseaseLast Updated:July 28, 2023Recruiting
Condition(s):Post-TURP Infectious ComplicationsLast Updated:December 13, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.